MedTrace Logo

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

NCT04973033 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-07-22

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of tofacitinib 5 mg twice daily in AAV patients.

Conditions

  • ANCA Associated Vasculitis
  • Drug Use
  • JAK-STAT Pathway Deregulation

Interventions

DRUG

Tofacitinib

patients enrolled were prescribed tofacitinib 5mg twice a day orally.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Lindi Jiang, PhD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973033 on ClinicalTrials.gov